Purple Biotech (PPBT) Assets (2014 - 2026)

Purple Biotech (PPBT) has reported Assets for 13 consecutive years, with $14.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 58.79% year-over-year to $14.2 million in Q2 2026; TTM through Jun 2026 was $14.2 million, a 58.79% decrease from a year earlier, with the FY2025 full-year figure at $17.6 million, down 52.56% from the prior year.
• Assets was $14.2 million for Q2 2026 at Purple Biotech, down from $14.4 million in the prior quarter.
• Over five years, Assets peaked at $66.3 million in Q1 2022 and troughed at $14.2 million in Q2 2026.
• A 5-year average of $40.8 million and a median of $39.5 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets rose 11.27% in 2025 and plunged 59.5% in 2026, its largest moves.
• Over 5 years, Assets stood at $54.6 million in 2022, then fell by 18.89% to $44.3 million in 2023, then declined by 16.4% to $37.0 million in 2024, then slumped by 52.56% to $17.6 million in 2025, then fell by 19.38% to $14.2 million in 2026.
• The last three Assets figures came in at $14.2 million (Q2 2026), $14.4 million (Q1 2026), and $17.6 million (Q4 2025), per Business Quant data.